Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Blood

Volumn 130, Issue 21, 2017, Pages 2243-2250

  Miklos, David ^a   Cutler, Corey S ^b   Arora, Mukta ^c   Waller, Edmund K ^d   Jagasia, Madan ^e   Pusic, Iskra ^f   Flowers, Mary E ^g   Logan, Aaron C ^h   Nakamura, Ryotaro ⁱ   Blazar, Bruce R ^c   Li, Yunfeng ^j   Chang, Stephen ^j   Lal, Indu ^j   Dubovsky, Jason ^j   James, Danelle F ^j   Styles, Lori ^j   Jaglowski, Samantha ^k  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d EMORY UNIVERSITY   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g USA   (United States)

^h UNIVERSITY OF SAN FRANCISCO   (United States)

ⁱ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^j PHARMACYCLICS INC   (United States)

^k OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; CD123 ANTIGEN; CD63 ANTIGEN; HLA DR ANTIGEN; IBRUTINIB; IMMUNOGLOBULIN E; INTERLEUKIN 2 INDUCIBLE T CELL KINASE; PREDNISONE; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; BIOLOGICAL MARKER; CORTICOSTEROID; EMT PROTEIN-TYROSINE KINASE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONSTIPATION; CORTICOSTEROID THERAPY; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HLA MATCHING; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; LEUKEMIA RELAPSE; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; SKIN BRUISING; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; DEMOGRAPHY; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADRENAL CORTEX HORMONES; ADULT; AGED; BIOMARKERS; CHRONIC DISEASE; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; YOUNG ADULT;

EID: 85034862360     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-07-793786     Document Type: Article

References (41)

1. Lee SJ. Have we made progress in the management of chronic graft-vs-host disease? Best Pract Res Clin Haematol. 2010;23(4):529-535.
2. Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011;117(24):6714-6720.
3. Socié G, Stone JV, Wingard JR, et al; Late Effects Working Committee of the International Bone Marrow Transplant Registry. Long-term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med. 1999;341(1):14-21.
4. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406-414.
5. Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108(8): 2867-2873.
6. Garnett C, Apperley JF, Pavlů J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013;4(6):366-378.
7. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7(5):265-273.
8. Gilman AL, Schultz KR, Goldman FD, et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children’s Oncology Group study. Biol Blood Marrow Transplant. 2012;18(1):84-91.
9. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood. 2000;96(12): 3995-3996.
10. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48-51.
11. Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009; 113(21):5074-5082.
12. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72(2):546-554.
13. Flowers ME, Storer B, Carpenter P, et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(12):1380-1384.
14. Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol. 2011;18(6):414-420.
15. Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4): 606-615.
16. Allen JL, Tata PV, Fore MS, et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood. 2014;123(13):2108-2115.
17. Flynn R, Du J, Veenstra RG, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123(25):3988-3998.
18. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005; 105(7):2973-2978.
19. Sarantopoulos S, Blazar BR, Cutler C, Ritz J. B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(1):16-23.
20. Pavletic SZ, Carter SL, Kernan NA, et al; National Heart, Lung, and Blood Institute Unrelated Donor Marrow Transplantation Trial. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106(9):3308-3313.
21. Baron F, Mohty M, Blaise D, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(2):224-234.
22. Nakasone H, Sahaf B, Miklos DB. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. Int J Hematol. 2015;101(5): 438-451.
23. Shinners NP, Carlesso G, Castro I, et al. Bruton’s tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family [published correction appears inJ Immunol. 2007;179(9):6369]. J Immunol. 2007;179(6):3872-3880.
24. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
25. Dubovsky JA, Flynn R, Du J, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014;124(11): 4867-4876.
26. Ryan CE, Sahaf B, Logan AC, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128(25):2899-2908.
27. Pavletic SZ, Martin P, Lee SJ, et al; Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12(3):252-266.
28. Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984-999.
29. Lee SJ, Kim HT, Ho VT, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006; 38(4):305-310.
30. Martin PJ, Inamoto Y, Carpenter PA, Lee SJ, Flowers ME. Treatment of chronic graft-versus-host disease: Past, present and future. Korean J Hematol. 2011;46(3):153-163.
31. Olivieri J, Manfredi L, Postacchini L, et al. Consensus recommendations for improvement of unmet clinical needs–the example of chronic graft-versus-host disease: a systematic review and meta-analysis. Lancet Haematol. 2015;2(7):e297-e305.
32. Martin PJ, Storer BE, Inamoto Y, et al. An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood. 2017;130(3):360-367.
33. Syrjala KL, Martin PJ, Lee SJ. Delivering care to long-term adult survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30(30): 3746-3751.
34. Bladon J, Taylor PC. The down-regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)treated lymphocytes, is not dependent on lymphocyte phosphatidylserine externalization. Transpl Int. 2006;19(4):319-324.
35. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group. Blood. 2008;111(6):3276-3285.
36. Castor MG, Pinho V, Teixeira MM. The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics. Front Pharmacol. 2012;3:23. doi:10.3389/ fphar.2012.00023. eCollection 2012.
37. Kariminia A, Holtan SG, Ivison S, et al. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR31 NK cells. Blood. 2016;127(24):3082-3091.
38. Miklos S, Mueller G, Chang Y, et al. Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease. Int J Hematol. 2009;89(3):383-397.
39. Ueha S, Murai M, Yoneyama H, et al. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects. J Leukoc Biol. 2007;81(1):176-185.
40. Cocho L, Fernández I, Calonge M, et al. Biomarkers in ocular chronic graft versus host disease: tear cytokine- and chemokine-based predictive model. Invest Ophthalmol Vis Sci. 2016;57(2):746-758.
41. MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017; 129(1):13-21.